Why longevity might be biopharma’s next big thing: The science and business converge
Longevity — once dismissed as the domain of futurists and fringe scientists — has rapidly emerged as one of the most compelling frontiers in drug development. The transformation hasn’t happened overnight, but since 2024, a convergence of scientific breakthroughs, regulatory evolution, and unprecedented commercial interest has propelled aging biology from academic curiosity to boardroom strategy.
The numbers tell part of the story: longevity-focused startups attracted $8.5 billion in venture capital in 2024 alone, more than doubling from the previous year’s downturn. The broader longevity market is projected to grow from $5.3 trillion in 2023 to $8 trillion by 2030. But beyond the capital flows, something more fundamental has shifted. Major pharmaceutical companies are no longer hedging their bets on aging biology—they’re building entire divisions around it.
The GLP-1 revelation: Aging biology goes mainstream
Perhaps nothing has done more to legitimize longevity therapeutics than the explosive success of GLP-1 receptor agonists. Drugs like Ozempic, Wegovy, and Mounjaro were initially developed for diabetes and obesity, but their benefits extend far beyond weight loss. By 2025, the evidence had become impossible to ignore: these medications were demonstrating effects across multiple hallmarks of aging simultaneously.
The cardiovascular protection alone has been striking. Landmark trials showed GLP-1s reducing major adverse cardiovascular events by 13-26%, with benefits extending even to non-diabetic individuals. But the story goes deeper. These drugs reduce chronic inflammation, improve kidney function, reverse fatty liver disease, and show emerging neuroprotective properties that could address cognitive decline.
Most remarkably, GLP-1s may be the first class of medications to directly target biological aging mechanisms. Research published in 2024-2025 revealed that SGLT2 inhibitors—a related drug class—can eliminate senescent “zombie” cells through enhanced immune surveillance, extend telomeres in human clinical trials, and prolong lifespan in animal models by up to 14%. One study showed that henagliflozin lengthened telomeres in 90.5% of participants after just 26 weeks, compared to 65.6% in the placebo group.
The implications were seismic. Indeed, GLP-1s appear to recalibrate metabolic health and visceral fat distribution, reduce inflammation while protecting cardiovascular and kidney function, lower liver fat and fibrosis, and may even enhance cognitive resilience. These aren’t side benefits—they’re evidence that modulating fundamental nutrient-sensing pathways can reshape the trajectory of aging itself.
Eli Lilly and Novo Nordisk haven’t missed the significance. Both companies have explicitly embraced the “longevity” framing for their GLP-1 programs, pushing well beyond diabetes and obesity into the territory of healthspan extension. The message is clear: aging biology has moved from the periphery to the strategic core.
Big Pharma builds aging divisions
The pharmaceutical industry’s embrace of longevity extends well beyond repurposing existing drugs. Novartis launched its Diseases of Aging and Regenerative Medicine (DARe) division, explicitly focused on discovering novel therapeutic targets from aging biology. This isn’t a small exploratory team — it’s a strategic commitment backed by major partnership deals.
In December 2024, Novartis announced a collaboration with BioAge Labs that could be worth up to $550 million, providing $20 million upfront to access BioAge’s human longevity datasets and discover drug targets at the intersection of aging and exercise biology. The partnership aims to identify molecular factors that mediate the positive effects of exercise — essentially finding pharmacological shortcuts to exercise benefits that decline with age.
BioAge’s platform exemplifies the new paradigm: rather than starting with disease and working backward, these companies identify people who age exceptionally well, measure thousands of biological molecules longitudinally, and use computational tools to extract potential therapeutic targets. It’s precision medicine meets geroscience, and pharma companies are paying attention.
Eli Lilly has taken a similar approach through its ExploR&D collaborative division, partnering with BioAge to develop therapeutic antibodies targeting metabolic aging pathways. The company is also running combination trials pairing its blockbuster GLP-1 drug tirzepatide (AKA Mounjaro/Zepbound) with experimental compounds designed to preserve muscle mass during weight loss — a critical concern for older adults taking these medications.
The AI-driven drug discovery milestone
While repurposed drugs have opened eyes, de novo drug discovery targeting aging mechanisms has provided crucial validation. In September 2024, Insilico Medicine announced positive Phase IIa results for ISM001-055 (now called Rentosertib), a TNIK inhibitor designed entirely using generative AI to treat idiopathic pulmonary fibrosis.
The results were extraordinary: patients receiving the highest dose showed a mean improvement in lung function of 98.4 mL compared to a decline of 62.3 mL in the placebo group after just 12 weeks. More importantly, the drug targeted TNIK—a kinase implicated in fibrotic diseases and aging processes—representing a completely novel therapeutic approach identified through computational analysis of aging biology.
“While we expected the drug to be safe, we did not expect to see such a clear dose-dependent efficacy signal after such a short dosing period,” said Insilico CEO Alex Zhavoronkov. “With our novel TNIK inhibitor, we attempted to go after what we think is a common mechanism in fibrotic diseases and in aging to maximize indication expansion potential”.
The study was published in Nature Medicine in June 2025, cementing its scientific credibility. This represented a watershed: an AI-discovered drug targeting aging mechanisms had demonstrated clinical efficacy in humans in less than four years from target identification to Phase IIa readout. The traditional drug development timeline had been compressed dramatically, and the target itself emerged from aging biology rather than disease-focused research.
Senolytics enter human testing
Cellular senescence — the accumulation of damaged “zombie” cells that secrete inflammatory factors—has been one of the most rigorously validated hallmarks of aging in animal models. By 2025, the first human trials of precision senolytic drugs were underway, moving the field beyond preclinical promise.
Rubedo Life Sciences dosed its first patient in a Phase 1 trial of RLS-1496 in June 2025, making it the first GPX4 modulator to enter human studies. The drug works through a sophisticated mechanism: it targets pathological senescent cells by modulating ferroptosis, a form of cell death driven by lipid peroxidation. Rather than indiscriminately clearing all senescent cells, Rubedo’s approach uses single-cell profiling to identify and eliminate only the toxic variants.
The trial design itself signals maturity in the field. Rather than starting with healthy volunteers, Rubedo is conducting a “basket” Phase 1 study that evaluates multiple skin conditions in parallel—including psoriasis, atopic dermatitis, and photoaged skin—allowing early assessment of therapeutic potential across the inflammation-aging spectrum. If successful, the company plans to advance systemic formulations in 2026 targeting obesity, pain, and other age-related conditions.
Unity Biotechnology, one of the earliest senolytics companies, reported encouraging Phase 2b results for UBX1325 in diabetic macular edema in March 2025. While the primary endpoint narrowly missed statistical significance at one timepoint, the drug demonstrated visual acuity gains exceeding five letters and achieved non-inferiority to the standard anti-VEGF therapy at nine out of ten timepoints through 36 weeks—with a favorable safety profile and no cases of inflammation.
These results matter because they demonstrate that senolytic approaches can show clinical benefit in humans when applied locally to specific tissues. The next frontier is systemic delivery for broader age-related conditions.
Epigenetic reprogramming approaches the clinic
Perhaps the most ambitious longevity approach — partial epigenetic reprogramming — has advanced rapidly toward human trials. The concept is elegant but technically challenging: use transcription factors (typically variants of the Yamanaka factors) to reset cellular age without inducing pluripotency or cancer risk.
Life Biosciences announced in late 2025 that it would initiate first-in-human clinical trials of ER-100 for optic neuropathies in the first quarter of 2026. The gene therapy delivers three transcription factors (Oct-4, Sox-2, and Klf-4) via intravitreal injection combined with systemic doxycycline to control expression timing.
Preclinical data presented at multiple conferences in 2025 showed that ER-100 restored visual function in nonhuman primate models of nonarteritic anterior ischemic optic neuropathy (NAION), improved retinal ganglion cell function, and restored methylation patterns enriched for neuronal regeneration. The company is also developing ER-300 for metabolic liver disease, with data showing significant improvements in liver enzymes and fibrosis scores in mouse models.
NewLimit, backed by Coinbase CEO Brian Armstrong with $280 million in cumulative funding, has taken a slightly different approach focused on epigenetic reprogramming for liver and immune system rejuvenation. The company screened over 3,000 transcription factor combinations and identified more than 20 sets capable of restoring youthful function in hepatocytes and T cells. By December 2025, NewLimit reported it was “close” to having clinic-ready epigenetic reprogramming therapies.
Altos Labs — the $3 billion cellular rejuvenation company backed by Jeff Bezos and other tech luminaries—signaled its shift toward clinical development by appointing Dr. Joan Mannick as Chief Medical Officer in mid-2025. Mannick’s extensive experience designing aging-focused clinical trials, including her leadership at resTORbio and Tornado Therapeutics, suggests Altos is preparing to advance its partial reprogramming programs into human studies.
Government backing accelerates the field
Federal support has provided crucial validation and resources. In December 2024, ARPA-H launched the PROSPR (PROactive Solutions for Prolonging Resilience) program with the explicit goal of extending American healthspan by 20 years. The program aims to identify physiological and biochemical markers of aging, develop assessment technologies, and accelerate therapeutics designed to enhance healthspan.
ARPA-H committed up to $52 million to the Buck Institute’s PATH (Personalized Analytics for Transforming Health) project, which will recruit a cohort of healthy individuals aged 50+ and track them with wearables and advanced analytics to predict and prevent chronic diseases before they manifest. The economic rationale is compelling: extending healthspan by just one year in 10% of the aging population would reduce entitlement program costs by $29 billion annually and add $80 billion to the economy.
As ARPA-H Director Dr. Renee Wegrzyn noted, “Researchers and scientists are looking to find new ways to detect and treat the large number of non-disease negative consequences of aging, like functional declines in memory, hearing, and muscle strength”. The recognition that pre-disease functional decline is a legitimate therapeutic target represents a significant regulatory evolution.
The biomarker and regulatory breakthrough
Perhaps the most critical development enabling longevity therapeutics is regulatory progress on aging biomarkers. The FDA and EMA have begun accepting sensor-derived measures including gait speed, heart rate variability, and sleep patterns as clinical endpoints. More significantly, advocacy efforts in 2024-2025 pushed for a comprehensive framework to validate biomarkers of biological aging as surrogate endpoints.
The problem has always been timescale: demonstrating that a drug extends healthy lifespan requires decades of follow-up, making development economically unfeasible. But if validated biomarkers can predict long-term outcomes, trials could be completed in years rather than decades. As one policy brief argued, “Just as the discovery of LDL as a surrogate marker of heart health was critical in enabling the testing and development of statins, the discovery of clinical-grade biomarkers may unlock new therapeutics designed to target the mechanisms that drive human aging”.
The acceptance of aging biomarkers as endpoints is already influencing trial design. BioAge’s obesity trials incorporate exploratory measures of biological age and inflammation. Life Biosciences’ epigenetic reprogramming studies track methylation age alongside disease-specific outcomes. Companies are building the evidence base that will eventually allow direct approval for “aging” or “healthspan extension” indications rather than requiring disease-specific endpoints.
Capital markets open for longevity
The return of IPO markets in 2024-2025 provided crucial liquidity for longevity biotechs. BioAge Labs went public in September 2024, raising $198 million at an $18 per share valuation that placed the company’s market cap at $606 million. The offering was led by Goldman Sachs, Morgan Stanley, Jefferies, and Citigroup—major financial institutions betting on aging biology.
BioAge’s IPO came just two months after its $170 million Series D round, demonstrating sustained investor appetite despite the company’s December 2024 decision to halt its Phase 2 obesity trial of azelaprag due to liver enzyme elevations. Rather than cratering, the company pivoted to next-generation APJ agonists and NLRP3 inflammasome inhibitors while leveraging its pharma partnerships to sustain momentum.
Jupiter Neurosciences and Loyal (focused on extending canine lifespan) also completed IPOs in 2024, while companies like Rubedo Life Sciences closed significant late-stage private rounds. As one analyst noted, “IPOs are coming back and I’m expecting more to come from the longevity field — we’re just at the beginning of the longevity biotech market”.
The hallmarks of aging framework provides a roadmap
Underlying all these developments is a robust scientific foundation. The 2013 publication identifying nine hallmarks of aging — genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, deregulated nutrient-sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, and altered intercellular communication — provided a framework that was updated to twelve hallmarks by 2023, adding chronic inflammation, disabled macroautophagy, and dysbiosis.
This framework has proven remarkably generative for drug discovery. Each hallmark represents a potential therapeutic target, and interventions addressing multiple hallmarks simultaneously show the greatest efficacy. GLP-1s modulate nutrient sensing, reduce inflammation, and may enhance autophagy. Senolytics eliminate senescent cells. Epigenetic reprogramming addresses epigenetic alterations and potentially resets multiple aging processes. NAD+ boosters target mitochondrial dysfunction and proteostasis.
The interconnectedness of aging hallmarks means that single interventions can produce cascading benefits across multiple systems — exactly what GLP-1s have demonstrated and what has captured pharma’s attention.
The road ahead: From hype to healthcare
The longevity sector still faces substantial challenges. Most therapies remain in early clinical development, with years of trials ahead before regulatory approval. The FDA’s lack of an “aging” indication means companies must pursue specific diseases as primary endpoints. Safety profiles for chronic use in generally healthy populations require extensive validation. And the field must avoid overpromising while building the evidence base.
But the momentum is undeniable. As one expert summarized 2025: “Longevity biotech exceeded my expectations in how quickly it went mainstream within big pharma, largely because the GLP-1 era made it obvious that metabolism, inflammation, and aging biology are deeply connected”. Another noted, “I was surprised in a good way by how quickly big pharma and the government started treating longevity biology as a core R&D strategy”.
Multiple aging biology programs entered mid-stage clinical trials in 2025, moving beyond early safety studies into trials assessing functional outcomes. Strategic partnerships between longevity startups and major pharmaceutical companies signaled that healthspan has moved from fringe to mainstream R&D. And critically, these partnerships are happening because companies frame their work around aging biology, not despite it.
The convergence of scientific validation (GLP-1 multi-system benefits, AI-discovered drugs proving efficacy, senolytics entering human trials), business momentum (pharma divisions focused on aging, major partnerships, successful IPOs), regulatory evolution (biomarker acceptance, ARPA-H programs), and economic necessity (aging population healthcare costs) has created conditions for longevity therapeutics to transition from research curiosity to clinical reality.
The next five years will determine whether aging biology fulfills its promise as a new therapeutic paradigm. But the groundwork laid since 2024 suggests we’re witnessing not just another biotech trend, but a fundamental reorientation of how medicine approaches health, disease, and the human lifespan itself.
The question is no longer whether longevity will become a major biopharma focus—it already has. The question now is which approaches will reach patients first, and how quickly the field can deliver on the extraordinary promise that has captured the attention and capital of an entire industry.
Learn more about how Cortellis Deals Intelligence helps pharmas and biotechs understand the dealmaking landscape: Cortellis Pharma Deals Intelligence & Analytics | Clarivate
Related insights
The latest news, technologies, and resources from our team.
